Bouter, Yvonne

[["dc.bibliographiccitation.artnumber","17338"],["dc.bibliographiccitation.journal","Scientific Reports"],["dc.bibliographiccitation.volume","5"],["dc.contributor.author","Antonios, Gregory"],["dc.contributor.author","Borgers, Henning"],["dc.contributor.author","Richard, Bernhard Clemens"],["dc.contributor.author","Brauss, Andreas"],["dc.contributor.author","Meissner, Julius"],["dc.contributor.author","Weggen, Sascha"],["dc.contributor.author","Pena, Vladimir"],["dc.contributor.author","Pillot, Thierry"],["dc.contributor.author","Davies, Sarah L."],["dc.contributor.author","Bakrania, Preeti"],["dc.contributor.author","Matthews, David"],["dc.contributor.author","Brownlees, Janet"],["dc.contributor.author","Bouter, Yvonne"],["dc.contributor.author","Bayer, Thomas A."],["dc.date.accessioned","2018-11-07T09:47:52Z"],["dc.date.available","2018-11-07T09:47:52Z"],["dc.date.issued","2015"],["dc.description.abstract","Full-length A beta 1-42 and A beta 1-40, N-truncated pyroglutamate A beta 3-42 and A beta 4-42 are major variants in the Alzheimer brain. A beta 4-42 has not been considered as a therapeutic target yet. We demonstrate that the antibody NT4X and its Fab fragment reacting with both the free N-terminus of A beta 4-x and pyroglutamate A beta 3-X mitigated neuron loss in Tg4-42 mice expressing A beta 4-42 and completely rescued spatial reference memory deficits after passive immunization. NT4X and its Fab fragment also rescued working memory deficits in wild type mice induced by intraventricular injection of A beta 4-42. NT4X reduced pyroglutamate A beta 3-x, A beta x-40 and Thioflavin-S positive plaque load after passive immunization of 5XFAD mice. A beta 1-x and A beta x-42 plaque deposits were unchanged. Importantly, for the first time, we demonstrate that passive immunization using the antibody NT4X is therapeutically beneficial in Alzheimer mouse models showing that N-truncated A beta starting with position four in addition to pyroglutamate A beta 3-x is a relevant target to fight Alzheimer's disease."],["dc.description.sponsorship","Open-Access Publikationsfonds 2015"],["dc.identifier.doi","10.1038/srep17338"],["dc.identifier.isi","000365638800001"],["dc.identifier.pmid","26626428"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/12643"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/35186"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.relation.issn","2045-2322"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Alzheimer therapy with an antibody against N-terminal Abeta 4-X and pyroglutamate Abeta 3-X"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]